Prurigo

Summary

Prurigo (MONDO:0021739) is a disease with 2 GWAS associations across 6 studies and 6 clinical trials. Top therapeutic interventions include abrocitinib, nalbuphine, and ruxolitinib. A subtype of exanthem — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 2
• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	prurigo
Mondo ID	MONDO:0021739
MeSH	D011536
ICD-11	268810206
SNOMED CT	64144002
UMLS	C0033771
MedGen	10986
Is cancer (heuristic)	no

Also known as: Itchy skin eruption · prurigo · Pruritic rash · pruritic rash

Data availability: 2 GWAS associations (6 studies).

Disease family

This is a subtype of exanthem. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › exanthem › prurigo

Related subtypes (12): exanthema subitum, variola major infectious disease, pityriasis versicolor, bacterial exanthem, pityriasis rosea, viral exanthem, pityriasis lichenoides, pityriasis simplex, pityriasis folliculorum, pityriasis amiantacea, pityriasis alba, pityriasis steatoides

Genetics & variants

GWAS landscape

2 GWAS associations across 6 studies. Top hits map to 0 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs184889746	4e-31	HLA-DRB9 - HLA-DRB5	T	0.6
chr6:32549362	7e-27		G	0.41

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90478795	Verma A	2024	7,448	432,972	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90476184	Verma A	2024	3,810	114,442	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90480455	Verma A	2024	3,810	114,442	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90478794	Verma A	2024	1,193	57,395	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90436602	Zhou W	2018	779	402,672	Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90727032	Kim HI	2026	701	43,325	Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	2

MAF distribution

Bucket	Variants
common (>=0.05)	1
low_freq (0.01-0.05)	1
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	1
unknown	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs184889746	6	32486608	T>C	0.012	intron_variant	HLA-DRB9 - HLA-DRB5	4e-31	Tier 4: intronic/intergenic
chr6:32549362				0.088			7e-27	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Dupilumab	Approved (phase 4)
Nemolizumab	Approved (phase 4)
Ruxolitinib	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Benralizumab.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2/PHASE3	2
PHASE2	2
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02174419	PHASE2/PHASE3	COMPLETED	Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
NCT02174432	PHASE2/PHASE3	COMPLETED	Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
NCT05755438	PHASE3	COMPLETED	A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
NCT05038982	PHASE2	COMPLETED	Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
NCT05528913	PHASE2	WITHDRAWN	Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC)
NCT03340155	Not specified	UNKNOWN	Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ABROCITINIB	4	1
NALBUPHINE	4	1
RUXOLITINIB	4	1
CHEMBL4637163	0	1